Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Irina Krykbaeva"'
Autor:
Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu, Harriet M. Kluger
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-15 (2023)
Abstract Background Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpos
Externí odkaz:
https://doaj.org/article/4fa1a648e79343f59ea5d04accc2e62b
Autor:
Orr-El Weizman, Sophia Luyten, Irina Krykbaeva, Eric Song, Tianyang Mao, Marcus Bosenberg, Akiko Iwasaki
Publikováno v:
The Journal of Immunology. 210:1146-1155
The progression of transformed primary tumors to metastatic colonization is a lethal determinant of disease outcome. Although circulating adaptive and innate lymphocyte effector responses are required for effective antimetastatic immunity, whether ti
Autor:
Qin Yan, Marcus W. Bosenberg, Daniel P. Kelly, Matthew D. Hall, Anton Simeonov, Stephen C. Kales, Daniel J. Jansen, Ling Lai, Irina Krykbaeva, Meaghan K. McGeary, Shang-Min Zhang, Xiaoni Liu
Tumor heterogeneity is a major challenge for cancer treatment, especially due to the presence of various subpopulations with stem cell or progenitor cell properties. In mouse melanomas, both CD34+p75− (CD34+) and CD34−p75− (CD34−) tumor subpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::067c56d0d5b3eb34e6f9c5b1dfc605d1
https://doi.org/10.1158/1535-7163.c.6538539.v1
https://doi.org/10.1158/1535-7163.c.6538539.v1
Autor:
Qin Yan, Marcus W. Bosenberg, Daniel P. Kelly, Matthew D. Hall, Anton Simeonov, Stephen C. Kales, Daniel J. Jansen, Ling Lai, Irina Krykbaeva, Meaghan K. McGeary, Shang-Min Zhang, Xiaoni Liu
Figure S1. Responses of different YUMM cell lines to BRAFi treatment; Figure S2. Inhibition of KDM5 family members by shRNA knockdown and pan-KDM5 inhibitors; Figure S3. Subpopulation composition in tumors of different volumes; Figure S4. In vivo BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e29b44f79f8fe1852f77e511980e40fd
https://doi.org/10.1158/1535-7163.22506975
https://doi.org/10.1158/1535-7163.22506975
Autor:
Harriet M. Kluger, Michael Hurwitz, Mario Sznol, Scott Gettinger, William Damsky, Curtis J. Perry, Susan M. Kaech, Marcus Bosenberg, Ovid Trifan, Amit Mahajan, Wei Wei, Daniel Zelterman, Gail Anderson, Neta Shanwetter Levit, Barbara Johnson, Amanda Ralabate, Lucia Jilaveanu, Lin Zhang, Irina Krykbaeva, Shlomit Jessel, Dijana Djureinovic, Sarah A. Weiss
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a043a703bb58c6fa6b9de5de2a58e8d7
https://doi.org/10.1158/1078-0432.22480427
https://doi.org/10.1158/1078-0432.22480427
Autor:
Harriet M. Kluger, Michael Hurwitz, Mario Sznol, Scott Gettinger, William Damsky, Curtis J. Perry, Susan M. Kaech, Marcus Bosenberg, Ovid Trifan, Amit Mahajan, Wei Wei, Daniel Zelterman, Gail Anderson, Neta Shanwetter Levit, Barbara Johnson, Amanda Ralabate, Lucia Jilaveanu, Lin Zhang, Irina Krykbaeva, Shlomit Jessel, Dijana Djureinovic, Sarah A. Weiss
Association between pre-treatment CD4+ T-cell density from available baseline tumor tissue (n=14) and the duration of time on treatment in days.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8b5eba52845695c761885ea1138d92
https://doi.org/10.1158/1078-0432.22480430.v1
https://doi.org/10.1158/1078-0432.22480430.v1
Autor:
Harriet M. Kluger, Michael Hurwitz, Mario Sznol, Scott Gettinger, William Damsky, Curtis J. Perry, Susan M. Kaech, Marcus Bosenberg, Ovid Trifan, Amit Mahajan, Wei Wei, Daniel Zelterman, Gail Anderson, Neta Shanwetter Levit, Barbara Johnson, Amanda Ralabate, Lucia Jilaveanu, Lin Zhang, Irina Krykbaeva, Shlomit Jessel, Dijana Djureinovic, Sarah A. Weiss
Trial Protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ae5b9093afbdaca00b04e264deed14
https://doi.org/10.1158/1078-0432.22480424
https://doi.org/10.1158/1078-0432.22480424
Autor:
Harriet M. Kluger, Michael Hurwitz, Mario Sznol, Scott Gettinger, William Damsky, Curtis J. Perry, Susan M. Kaech, Marcus Bosenberg, Ovid Trifan, Amit Mahajan, Wei Wei, Daniel Zelterman, Gail Anderson, Neta Shanwetter Levit, Barbara Johnson, Amanda Ralabate, Lucia Jilaveanu, Lin Zhang, Irina Krykbaeva, Shlomit Jessel, Dijana Djureinovic, Sarah A. Weiss
Waterfall plots demonstrating the percent change in sum of RECIST v1.1 target lesions compared to baseline. Twenty-five out of 26 patients were included; 1 patient withdrew consent and no follow-up imaging was available for review. The waterfall plot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bfe8780b9746221e86403dfbe8f293
https://doi.org/10.1158/1078-0432.22480442
https://doi.org/10.1158/1078-0432.22480442
Autor:
Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia Jilaveanu, Harriet M. Kluger
Publikováno v:
Cancer Research. 83:3287-3287
Stimulating innate immunity can potentially enable us to overcome resistance to PD-(L)1 blockade. We previously conducted a phase 1 trial of cabiralizumab (anti-CSF1R) with sotigalimab (CD40 agonistic antibody) and nivolumab. Our purpose was to deter
Autor:
Wei Wei, Amit Mahajan, Michael E. Hurwitz, Susan M. Kaech, Ovidiu C. Trifan, Barbara Johnson, William Damsky, Dijana Djureinovic, Sarah A. Weiss, Lin Zhang, Gail Anderson, Neta Shanwetter Levit, Lucia B. Jilaveanu, Curtis J. Perry, Amanda Ralabate, Daniel Zelterman, Shlomit Jessel, Marcus Bosenberg, Irina Krykbaeva, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol
Publikováno v:
Clin Cancer Res
Purpose: PD-1/PD-L1 inhibitors are approved for multiple tumor types. However, resistance poses substantial clinical challenges. Patients and Methods: We conducted a phase I trial of CD40 agonist APX005M (sotigalimab) and CSF1R inhibitor cabiralizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf4bd6fb6ebd68e8249c5eefad14aec
https://europepmc.org/articles/PMC9236708/
https://europepmc.org/articles/PMC9236708/